T. C. D. Toritto

发表

Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study

M. Boccadoro, A. Larocca, S. Bringhen, 2018, Blood.

Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02/HO95 Study

P. Bartolomeo, P. Sonneveld, S. Bringhen, 2017 .

Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study

M. Boccadoro, D. Rossi, A. Nagler, 2011 .

9200 ORAL A Phase 3 Study Comparing Melphalan-Prednisone-Lenalidomide (MPR) With High-dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Patients With Multiple Myeloma (MM)

M. Boccadoro, A. Nagler, D. B. Yehuda, 2011 .

Identifying the link between multiple myeloma and neurofibromatosis type I

A. Siniscalchi, A. Rago, C. Andrizzi, 2020, Blood research.

Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study

F. Alesiani, S. Felici, P. Tosi, 2014 .

BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STAUDY.

F. Alesiani, A. Ledda, M. Offidani, 2012 .

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

F. Alesiani, P. Tosi, A. Liberati, 2013, Blood Cancer Journal.